(Q36303134)

English

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

0 references

1 reference

based on heuristic

inferred from title

David R Gandara

2

object named as

David R Gandara

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

Everett E Vokes

8

object named as

Everett Vokes

1 reference

Europe PubMed Central

13 August 2017

PMC publication ID

1

object named as

Roy S Herbst

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Vassiliki Papadimitrakopoulou

26

object named as

Vassiliki A Papadimitrakopoulou

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

3

object named as

Fred R Hirsch

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

6

object named as

Philip C Mack

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Suresh S Ramalingam

9

object named as

Suresh S Ramalingam

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Charles D Blanke

25

object named as

Charles D Blanke

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Mary W Redman

4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Michael LeBlanc

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lawrence H Schwartz

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jeffrey D Bradley

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Dana Sparks

11

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Yang Zhou

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Crystal Miwa

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Vincent A Miller

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Roman Yelensky

15

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Yali Li

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jeff D Allen

17

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Ellen V Sigal

18

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

David Wholley

19

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Caroline C Sigman

20

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gideon M Blumenthal

21

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Shakun Malik

22

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Gary J Kelloff

23

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Jeffrey S Abrams

24

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

0 references

publication date

13 February 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

1514-1524

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

US lung cancer trends by histologic type

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Immune checkpoint inhibitors in NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Evaluating many treatments and biomarkers in oncology: a new design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

The impact of genomic changes on treatment of lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Genomics of squamous cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Designing transformative clinical trials in the cancer genome era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

The BATTLE trial: personalizing therapy for lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Genome-sequencing anniversary. Faces of the genome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

30 September 2017

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4654466

22 September 2018

Pathology of lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rilotumumab extends PFS in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time has come to raise the bar in oncology clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive results for drug combo in I-SPY 2 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular analysis for therapy choice: NCI MATCH

1 reference

https://pubmed.ncbi.nlm.nih.gov/25680375

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-13-3473

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36303134&oldid=1857353597"